Aspen Neuroscience

ASPENasdaq United States Health Care Biotechnology: Pharmaceutical Preparations

Market cap

$379.185 M

$13.04 -12.42%

Close of 3 Nov 2026

As of 3 Nov 2026, Aspen Neuroscience (ASPE) has a market capitalization of $379.2M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

—

Not reported

Earnings

—

Not reported

Shares outstanding

—

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Pharmaceutical Preparations, ranked by market cap

All 498 →

#209AltimmuneALT$392.9M
#210Avalo TherapeuticsAVTX$392.6M
#211Aspen NeuroscienceASPE$379.2M
#212RezoluteRZLT$375.3M
#213Contineum TherapeuticsCTNM$359.7M

Insiders buying

All insider buying →

2 open-market purchases by officers and directors of Aspen Neuroscience, worth $38.0M. Grants and option exercises are excluded.

ARCH Venture Fund X Overage, L.P., ARCH Venture Fund X, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Partners X, L.P., ARCH Venture Partners X, LLC, Kristina Burow, Keith Crandell, Steven Gillis, Robert Nelsen$20.0M
1,333,333 shares at $15.00 on 2 Nov 2026 · filed 2 Nov 2026
ARCH Venture Fund XIV, L.P., ARCH Venture Partners XIV, L.P., ARCH Venture Partners XIV, LLC, Paul L. Berns$18.0M
1,200,000 shares at $15.00 on 2 Nov 2026 · filed 2 Nov 2026

What if Aspen Neuroscience were worth as much as…

Open the what-if tool →

Gold $27.4T

$940,626.29

Per share 72,134× higher

Bitcoin $1.54T

$52,905.27

Per share 4,057× higher

Apple $4.94T

$169,798.51

Per share 13,021× higher

Or at a round number

$500.0M $1.00B $2.00B $5.00B

Where these numbers come from

Share counts and financials for Aspen Neuroscience are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.